ATM as a target for novel radiosensitizers

Seminars in Radiation Oncology

Volumn 11, Issue 4, 2001, Pages 316-327

  Sarkaria, Jann N ^a   Eshleman, Jeffrey S ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; PROTEIN KINASE INHIBITOR; RADIOSENSITIZING AGENT;

ARTICLE; ATAXIA TELANGIECTASIA; CANCER RADIOTHERAPY; CANCER RISK; DNA DAMAGE; HUMAN; IONIZING RADIATION; LEUKEMIA; LYMPHOMA; PRIORITY JOURNAL; RADIOSENSITIVITY; RADIOSENSITIZATION;

EID: 0034793238     PISSN: 10534296     EISSN: None     Source Type: Journal    
DOI: 10.1053/srao.2001.26030     Document Type: Article

References (100)

1. ATM - From gene to function
2. The genetic defect in ataxia-telangiectasia
3. Consequences of the delayed diagnosis of ataxia-telangiectasia
4. Allergy: Status and perspective
5. Immunoglobulin metabolism in ataxia telangiectasia
6. Mutations at the ataxia-telangiectasia locus and clinical phenotypes of A-T patients
7. Mortality and cancer incidence in 263 patients with ataxia-telangiectasia
8. Cancer in ataxia-telangiectasia patients
9. Treatment of lymphoid malignancies in patients with ataxia-telangiectasia
10. Cancer susceptibility in ataxia-telangiectasia
11. Clustering of missense mutations in the ataxia-telangiectasia gene in a sporadic T-cell leukaemia
12. ATM is usually rearranged in T-cell prolymphocytic leukaemia
13. Inactivation of the ATM gene in T-cell prolymphocytic leukemias
14. Deficiency of the ATM protein expression defines an aggressive subgroup of B-cell chronic lymphocytic leukemia
15. Inactivation of ataxia telangiectasia mutated gene in B-cell chronic lymphocytic leukaemia
16. Radiation reaction in ataxia telangiectasia
17. Ataxia telangiectasia. Neoplasia, untoward response to x-irradiation, and tuberous sclerosis
18. Ataxia telangiectasia with granulocytopenia
19. The effects of radiation therapy for Hodgkin's disease in a child with ataxia telangiectasia: A clinical, biological and pathologic study
20. ATM: The product of the gene mutated in ataxia-telangiectasia
21. Ataxia-telangiectasia, cancer and the pathobiology of the ATM gene
22. The complete sequence of the coding region of the ATM gene reveals similarity to cell cycle regulators in different species
23. Diversity of ATM gene mutations detected in patients with ataxia-telangiectasia
24. Identification of ATM mutations using extended RT-PCR and restriction endonuclease fingerprinting, and elucidation of the repertoire of A-T mutations in Israel
25. ATM mutations and phenotyes in ataxia-telangiectasia families in the British Isles: Expression of mutant ATM and the risk of leukemia, lymphoma, and breast cancer
26. Ataxia-telangiectasia: Identification and detection of founder-effect mutations in the ATM gene in ethnic populations
27. Predominance of null mutations in ataxia-telangiectasia
28. Analysis of the ATM protein in wild-type and ataxia telangiectasia cells
29. Isolation of full-length ATM cDNA and correction of the ataxia-telangiectasia cellular phenotype
30. Recombinant ATM protein complements the cellular A-T phenotype
31. PIK-related kinases: DNA repair, recombination and cell cycle checkpoints
32. Responses to DNA damage and regulation of cell cycle checkpoints by the ATM protein kinase family
33. A single ataxia telangiectasia gene with a product similar to PI-3 kinase
34. Targeted disruption of the catalytic subunit of the DNA-PK gene in mice confers severe combined immunodeficiency and radiosensitivity
35. The DNA damage response: Putting checkpoints in perspective
36. An N-terminal p14(ARF) peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo
37. Oncoprotein Mdm2 is a ubiquitin ligase E3 for tumor suppressor p53
38. Mdm2 promotes the rapid degradation of p53
39. Regulation of Mdm2-directed degradation by the C terminus of p53
40. Rapid ATM-dependent phosphorylation of MDM2 precedes p53 accumulation in response to DNA damage
41. Phosphorylation of Ser-20 mediates stabilization of human p53 in response to DNA damage
42. DNA damage induces phosphorylation of the amino terminus of p53
43. Linkage of ATM to the cell cycle regulation by the Chk2 protein kinase
44. A human Cds1-related kinase that functions downstream of ATM protein in the cellular response to DNA damage
45. Mammalian Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway
46. Chk1 is an essential kinase that is regulated by ATR and required for the G(2)/M DNA damage checkpoint
47. Conservation of the Chk1 checkpoint pathway in mammals: Linkage of DNA damage to Cdk regulation through Cdc25
48. Mitotic and G2 checkpoint control: Regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216
49. Ionizing radiation and cell cycle progression in ataxia telangiectasia
50. Overexpression of a kinase-inactive ATR protein causes sensitivity to DNA-damaging agents and defects in cell cycle checkpoints
51. Radiosensitivity in ataxia-telangiectasia: A new explanation
52. ATM phosphorylates p95/nbs1 in an S-phase checkpoint pathway
53. DNA double strand break repair in mammalian cells
54. Host cell reactivation of gamma-irradiated adenovirus 5 in human cell lines of varying radiosensitivity
55. Examination of vectors with two dominant, selectable genes for DNA repair and mutation studies in mammalian cells
56. The Hmre11/Hrad50 protein complex and Nijmegen breakage syndrome: Linkage of double-strand break repair to the cellular DNA damage response
57. Pathological and physiological double-strand breaks: Roles in cancer, aging, and the immune system
58. The many interfaces of Mre11
59. Ataxia-telangiectasia and the Nijmegen breakage syndrome: Related disorders but genes apart
60. The DNA double-strand break repair gene hMRE11 is mutated in individuals with an ataxia-telangiectasia-like disorder
61. Requirement of ATM-dependent phosphorytation of BRCA1 in the DNA damage response to double-strand breaks
62. Breast and ovarian cancer incidence in BRCA1-mutation carriers
63. hCds1-mediated phosphorylation of BRCA1 regulates the DNA damage response
64. Functional interactions between BRCA1 and the checkpoint kinase ATR during genotoxic stress
65. Splitting the ATM: Distinct repair and checkpoint defects in ataxia-telangiectasia
66. Wortmannin is a potent inhibitor of DNA double strand break but not single strand break repair in Chinese hamster ovary cells
67. The phosphatidylinositol 3-kinase inhibitor wortmannin sensitizes murine fibroblasts and human tumor cells to radiation and blocks induction of p53 following DNA damage
68. 2-M delay
69. DNA-dependent protein kinase catalytic subunit: A relative of phosphatidylinositol 3-kinase and the ataxia telangiectasia gene product
70. Inhibition of phosphoinositide 3-kinase related kinases by the radiosensitizing agent wortmannin
71. Wortmannin inhibits repair of DNA double-strand breaks in irradiated normal human cells
72. Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine
73. Caffeine inhibits the checkpoint kinase ATM
74. Caffeine abolishes the mammalian G(2)/M DNA damage checkpoint by inhibiting ataxia-telangiectasia-mutated kinase activity
75. Differential sensitivity of p53(-) and p53(+) cells to caffeine-induced radiosensitization and override of G2 delay
76. Selective radiosensitization of p53-deficient cells by caffeine-mediated activation of p34cdc2 kinase
77. Abrogation of the G2 checkpoint results in differential radiosensitization of G1 checkpoint-deficient and G1 checkpoint-competent cells
78. Preferential radiosensitization of G1 checkpoint-deficient cells by methylxanthines
79. Caffeine enhanced radiosensitivity of rat tumor cells with a mutant-type p53 by inducing apoptosis in a p53-independent manner
80. Inhibition of radiation-induced G2 delay potentiates cell death by apoptosis and/or the induction of giant cells in colorectal tumor cells with disrupted p53 function
81. A phase III comparison trial of streptozotocin, mitomycin, and 5-fluorouracil with cisplatin, cytosine arabinoside, and caffeine in patients with advanced pancreatic carcinoma
82. Cisplatin, cytarabine, caffeine, and continuously infused 5-fluorouracil (PACE) in the treatment of advanced pancreatic carcinoma: A phase II study
83. Caffeine-potentiated radiochemotherapy and function-saving surgery for high-grade soft tissue sarcoma
84. Marginal excision for osteosarcoma with caffeine assisted chemotherapy
85. A phase II evaluation of pentoxifylline combined with radiation in the treatment of brain metastases
86. Cranial radiation and concomitant cisplatin and mitomycin-C plus resistance modulators for malignant gliomas
87. Increases in tumor response by pentoxifylline alone or in combination with nicotinamide
88. Improved tumour oxygenation and radiosensitization by combination with nicotinamide and pentoxifylline
89. Increase in tumor oxygenation and radiosensitivity caused by pentoxifylline
90. Effect of pentoxifylline on radiation response of non-small cell lung cancer: A phase III randomized multicenter trial
91. Effects of lisofylline on hyperoxia-induced lung injury
92. A randomized placebo-controlled trial of lisofylline in HLA-identical, sibling-donor, allogeneic bone marrow transplant recipients
93. Lisofylline sensitizes p53 mutant human ovarian carcinoma cells to the cytotoxic effects of cis-diamminedichloroplatinum
94. 2 checkpoint function in cancer cells with disrupted p53
95. UCN-01 enhances the in vitro toxicity of clinical agents in human tumor cell lines
96. Phase I trial of infusional UCN-01, a novel protein kinase inhibitor, in patients with refractory neoplasms
97. Phase I study of UCN-01 by 3-hour infusion
98. The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01
99. The radiosensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1